The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Merck opens first climate-neutral manufacturing facility in Ireland
Subscribe To Our Newsletter & Stay Updated